US 11,654,123 B2
Method for inhibiting osteoclast development
John B. Barnett, Morgantown, WV (US); Harry C. Blair, Pittsburgh, PA (US); and Jonathan Soboloff, Cheltenham, PA (US)
Assigned to West Virginia University, Morgantown, WV (US); University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US); and Temple University—Of the Commonwealth System of Higher Education, Philadelphia, PA (US)
Filed by West Virginia University, Morgantown, WV (US); University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US); and Temple University—Of the Commonwealth System of Higher Education, Philadelphia, PA (US)
Filed on May 20, 2020, as Appl. No. 16/879,484.
Application 16/879,484 is a division of application No. 13/864,438, filed on Apr. 17, 2013, granted, now 10,682,320.
Claims priority of provisional application 61/635,525, filed on Apr. 19, 2012.
Prior Publication US 2020/0352884 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/167 (2006.01); A61P 19/08 (2006.01)
CPC A61K 31/167 (2013.01) 6 Claims
 
1. A method of inhibiting osteoclast development comprising:
administering an effective amount of a haloanilide composition or a salt thereof to an osteoclast cell for inhibiting osteoclast development, wherein said haloanilide composition is not N-(3,4-dichlorophenyl)propanamide, and wherein said haloanilide is a composition of Formula I, or salt thereof, comprising

OG Complex Work Unit Chemistry
wherein X is chlorine, Y is a methyl group, and R is an alkyl group having a carbon chain length of three carbon atoms.